COVID-19 Treatment: Eli Lilly Gets DCGI Emergency-Use Approval for Monoclonal Antibody Drugs Bamlanivimab 700 Mg and Etesevimab 1400 Mg

Eli Lilly gets DCGI emergency-use approval for antibody drugs to treat COVID-19

Eli Lilly gets Drugs Controller General of India (DCGI) emergency use approval for its monoclonal antibodies bamlanivimab 700 mg and etesevimab 1400 mg, in India for the treatment of COVID patients with moderate symptoms: Luca Visini, Managing Director, India Subcontinent, Lilly pic.twitter.com/arNU4eZhAc

— ANI (@ANI) June 1, 2021

(SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter (X), Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)